NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - General · USD

AstraZeneca PLC (AZN) Stock Analysis

AstraZeneca PLC (AZN) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

AZN

$168.45

−$0.37 (−0.22%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AZN with… →

AZN Key Statistics

As of Oct 21, 2026
Trading
Open
$168.91
Previous Close
$168.82
Day's Range
168.09–169.84
52-Week Range
153.41–212.71
Volume
1.85M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.21
Valuation
Market Cap
$261.82B
P/E Ratio
25.23
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
14.88
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.17
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.27
EPS (ttm)Profit attributable to each share over the last twelve months.
6.69
Financials (FY)
Revenue (FY)
$58.74B+8.63%
Net Income (FY)
$10.23B+45.34%
Profit marginThe share of revenue left as profit after all costs and taxes.
17.02%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.55B
1-Year Return
+2.26%
Dividend and dates
Dividend
$3.20+1.95%
Ex-Dividend Date
August 7, 2026
Earnings Date
October 30, 2026
Avg Volume
3.36M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AZN closed at $168.45, +2.26% over 1 year.

AstraZeneca PLC (AZN) has a market capitalization of $261.82B.

In fiscal 2025, AZN reported revenue of $58.74B.

AZN Stock Return by Calendar Year

AstraZeneca PLC (AZN) 10-year return: what $10,000 became

1 year
$10,000 $10,226
+2.26%
5 years
$10,000 $15,163
+51.63%
10 years
$10,000 $36,018
+260.18%

If you had invested $10,000 in AstraZeneca PLC (AZN) 10 years ago, at the close on October 21, 2016, it would have been worth $36,018 at the close on October 21, 2026: +260.18% in total, +13.67% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−7.43%
2025+43.30%
2024−0.62%
2023+1.44%
2022+19.16%
2021+19.73%
2020+3.12%
2019+35.68%
2018+13.86%
2017+33.24%
2016 (partial year)−19.75%

As of October 21, 2026.

AZN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$58.74B$10.23B17.4%
2024$54.07B$7.04B13.0%
2023$45.81B$5.96B13.0%
2022$44.35B$3.29B7.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$58.74B$48.11B$13.33B$10.23B17.4%
2024$54.07B$43.87B$10.25B$7.04B13.0%
2023$45.81B$37.54B$8.72B$5.96B13.0%
2022$44.35B$31.96B$4.51B$3.29B7.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AZN Dividend History

$3.13+5.4% vs 2024

Dividends per share, 2025 · 2 payments

YearDividends per sharePaymentsChange
2026*$2.151—
2025$3.132+5.4%
2024$2.972+2.4%
2023$2.902+0.0%
YearDividends per sharePaymentsChange
2026 (partial year)$2.151—
2025$3.132+5.4%
2024$2.972+2.4%
2023$2.902+0.0%
2022$2.902+3.6%
2021$2.802+0.0%
2020$2.802+0.0%
2019$2.802+0.0%
2018$2.802+0.0%
2017$2.802—

Most recent payment: $2.15 per share, ex-dividend February 19, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

AZN Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricAZNDrug Manufacturers - General medianvs median
P/E25.2325.230% above
P/S ratio4.273.2332% above
Profit margin17.02%9.80%7.2 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

AstraZeneca PLC (AZN) carries a market capitalisation of $261.82B. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. The company reports 96,100 employees.

The 52-week range on file runs from $153.41 to $212.71. The most recent close on file for AZN is $168.45, dated October 21, 2026. That is −$0.37 (−0.22%) against the previous close. The latest close sits 9.8% above that 52-week low.

Financial Health

In fiscal 2025, AstraZeneca PLC reported revenue of $58.74B. Against the prior fiscal year total of $54.07B, that is a change of +8.63%. The same year closed with net income of $10.23B. That is +45.34% against the prior fiscal year. The reported profit margin is 17.02%. That is 7.2 percentage points above the Drug Manufacturers - General median of 9.8%. Earnings per share on a trailing basis come to 6.69.

Across the 4 fiscal years on file, revenue moves from $44.35B in 2022 to $58.74B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 25.23. That is 0% above the Drug Manufacturers - General median of 25.23. The forward P/E on file is 14.88. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.17. Measured against sales, the shares trade at 4.27 times revenue. On price-to-sales that is 32.12% above the Drug Manufacturers - General median of 3.23. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +2.26%. Across 10 years the annualized return works out at +13.67%. Beta against the wider market is reported at 0.21. Daily returns over the trailing 10 years annualize to a volatility of 25.21%.

Growth & Income

AZN pays a dividend yielding 1.95%. That is 0.3 percentage points below the Drug Manufacturers - General median yield of 2.3%. At the indicated rate that is $3.20 a share a year. The ex-dividend date on file is August 7, 2026. Dividends are recorded for 10 calendar years; 2026 shows 1 payments totalling $2.15 a share. The year before, 2025, totalled $3.13 a share.

So far in 2026 the total return is −7.43%. Across the complete calendar years on file, 2025 returned +43.30% and 2024 returned −0.62%. Of the 9 complete calendar years on file, 8 finished higher.

Peer Comparison

AstraZeneca PLC (AZN) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AstraZeneca PLC AZN $261.82B 25.2
Eli Lilly and Company LLY $1.13T 42.7
Johnson & Johnson JNJ $621.22B 39.1
AbbVie Inc. ABBV $503.27B 80.5

The Drug Manufacturers - General industry average P/E ratio is 25.2x. AstraZeneca PLC trades at a P/E of 25.2.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 MRK

Merck & Co., Inc.

$369.78B

 NVS

Novartis AG

$292.58B

 AMGN

Amgen Inc.

$236.98B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$374.30B

 TMO

Thermo Fisher Scientific Inc.

$256.61B

 GILD

Gilead Sciences, Inc.

$190.42B

 ABT

Abbott Laboratories

$173.92B

 NVO

Novo Nordisk A/S

$172.38B
View all Healthcare stocks →

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates, with the potential to treat diseases across multiple indications; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Visit website →